Renfeng Guo
Founder chez INFLARX N.V.
Fortune : 3 M $ au 31/03/2024
Profil
Renfeng Guo founded InflaRx GmbH in 2007, where he worked as Chief Scientific Officer from 2009 to 2012 and InflaRx NV in 2007, where he is working as Executive Director & Chief Scientific Officer from 2007.
Dr. Guo also formerly worked at the University of Michigan, as Associate Professor.
Dr. Guo received his doctorate degree from Norman Bethune Medical University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
INFLARX N.V.
2,99% | 31/12/2023 | 1 762 144 ( 2,99% ) | 3 M $ | 31/03/2024 |
Postes actifs de Renfeng Guo
| Sociétés | Poste | Début |
|---|---|---|
| INFLARX N.V. | Founder | 01/12/2007 |
Anciens postes connus de Renfeng Guo
| Sociétés | Poste | Fin |
|---|---|---|
| University of Michigan | Corporate Officer/Principal | - |
InflaRx GmbH
 InflaRx GmbH BiotechnologyHealth Technology InflaRx GmbH operates as a biotech company which develops new therapeutics in the field of inflammation. It focuses on the general area of inflammation including indications such as SIRS and SEPSIS by applying innovative therapeutics in order to prevent organ dysfunction or limit progression into organ failure. The firm's complement system is activated and produces large amounts of products including complement 5a (C5a), C3a, C4a and membrane-attack complex (MAC). The company was founded in 2007 by Niels Riedemann and Renfeng Guo and is headquartered in Jena, Germany. | Founder | - |
Formation de Renfeng Guo
| Norman Bethune Medical University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| INFLARX N.V. | Health Technology |
| Entreprise privées | 1 |
|---|---|
InflaRx GmbH
InflaRx GmbH BiotechnologyHealth Technology InflaRx GmbH operates as a biotech company which develops new therapeutics in the field of inflammation. It focuses on the general area of inflammation including indications such as SIRS and SEPSIS by applying innovative therapeutics in order to prevent organ dysfunction or limit progression into organ failure. The firm's complement system is activated and produces large amounts of products including complement 5a (C5a), C3a, C4a and membrane-attack complex (MAC). The company was founded in 2007 by Niels Riedemann and Renfeng Guo and is headquartered in Jena, Germany. | Health Technology |
